Monographie - Epirubicin hydrochloride

Ostatnia aktualizacja :
19/11/2024

Epirubicin hydrochloride

Struktura chemiczna

Nazwa handlowa

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Anthracine	Malezja
Axirubicine	Niemcy
Bendaepi	Niemcy
Binarin	Meksyk
Bioepycina	Polska
Crisabon	Argentyna
Cuatroepi	Argentyna
Ecclepia	Rumunia
Elebicin	Meksyk
Ellence	Stany Zjednoczone Ameryki
Epi Cell	Niemcy
Epidoxo	Argentyna, Chile, Wenezuela
Epifil	Ekwador
Epilem	KolumbiaKolumbia, Meksyk
Epimedac	Niemcy
Epirubicin	Arabia Saudyjska, Australia, Austria, Belgia, Dania, Islandia, nowa Zelandia, Szwajcaria, Szwecja, Turcja, Węgry, Wielka Brytania
Epirubicina	Argentyna, Ekwador, Hiszpania, KolumbiaKolumbia, Meksyk, Rumunia
Epirubicine	Belgia, Francja , Szwajcaria
Farmarubicin	Turcja
Farmorubicin	Arabia Saudyjska, Austria, Brazylia, Dania, Finlandia, Grecja, Norwegia, Szwajcaria, Szwecja
Farmorubicin CSV	Afryka Południowa
Farmorubicin PFS	Chorwacja, Polska, Słowenia
Farmorubicin RD	Brazylia, Polska, rosyjski, Szwajcaria
Farmorubicin RTU	Holandia
Farmorubicina	Brazylia, Hiszpania, Portugalia, Włochy
Farmorubicine	Belgia, Francja
Pharmorubicin	Wielka Brytania

Bibliografia : Epirubicin hydrochloride

	typ	publikacja
148	Czasopismo	Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags. Pharm Weekbl [Sci] 1992 ; 14: 365-369.
525	Czasopismo	De Vroe C, De Muynck C, Remon JP, Samsom M. A study on the stability of three antineoplastic drugs and on their sorption by IV delivery systems and end-line filters. Int J Pharm 1990 ; 65: 49-56.
683	Czasopismo	Walker SE, Lau DWC, DeAngelis C, Iazetta J, Coons C. Epirubicin stability in syringes and glass vials and evaluation of chemical contamination. Can J Hosp Pharm 1990 ; 43: 265-272.
686	Czasopismo	Wood MJ, Irwin WJ, Scott DK. Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags. J Clin Pharm Ther 1990 ; 15: 279-289.
887	Czasopismo	Pujol M, Munoz M, Prat J, Giona V, De Bolos J. Stability study of epirubicin in NaCl 0.9% injection. Ann Pharmacotherapy 1997 ; 31: 992-995.
1237	Czasopismo	Keusters L, Stolk LML, Umans R, Van Asten P. Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20°C and thawing by microwave radiation. Pharm Weekbl [Sci] 1986 ; 8: 194-197.
1265	Czasopismo	Wood MJ, Irwin WJ, Scott DK. Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography. J Clin Pharm Ther 1990 ; 15: 291-300.
1317	Czasopismo	Adams PS, Haines-Hutt RF, Bradford E, Palmer A, Rowland CG. Pharmaceutical aspects of home infusion therapy for cancer patients. Pharm J 1987 ; 238: 476-478.
1662	Czasopismo	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1823	Czasopismo	Sewell GJ, Rigby-Jones AE, Priston MJ. Stability of intravesical epirubicin infusion: a sequential temperature study. J Clin Pharm Ther 2003 ; 28: 349-353.
1897	Czasopismo	Sautou-Miranda V, Brigas F, Thibault M, Chopineau J. Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage. EJHP 2001 ; 7, 3: 108-115.
1955	Czasopismo	Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann Pharmacotherapy 2005 ; 39: 280-283.
2168	Czasopismo	Ozdemir FA, Anilanmert B, Pekin M. Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2257	Laboratorium	Stability of epirubicin "Ebewe" infusion solutions. Ebewe Pharma 2007
3473	Czasopismo	Bennis Y, Savry A, Correard F, Montana M, Sauzet C, Gauthier-Villano L, Pisano P, Pourroy B. Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization. Int J Pharm 2015 ; 495, 2: 956-962.
3474	Laboratorium	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3632	Laboratorium	Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics Hospira 2017
3670	Czasopismo	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3708	plakat	Sarakbi I, Thiesen J, Krämer I. Compatibility of epirubicin-loaded DC Beads with different contrast media. ECOP 2 Krakow 2014
3918	Czasopismo	Sarakbi I, Krämer I. Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media. J Oncol Pharm Practice 2016 ; 22: 749-756.
4352	Czasopismo	Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y. In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag. J Clin Pharm Ther 2019 ; 44: 875-882.

Mentions Légales